Intestinal Flora and Metabonomics of Appendicitis
Launched by HONGYIQU · Sep 5, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the types of bacteria and metabolites (small molecules produced by metabolism) in the intestines of children with appendicitis. Researchers want to find out what specific bacteria and substances are linked to appendicitis in young patients. They will compare samples from children diagnosed with appendicitis to those from healthy children to identify key differences. This study is important because it may help doctors in the future to better diagnose and treat appendicitis in children.
To participate, children aged 1 to 14 who have been diagnosed with appendicitis and have undergone a specific surgery called laparoscopic appendectomy are eligible. Children without digestive tract diseases and a history of such issues may also be included. However, children with certain conditions, such as a family history of intestinal diseases or those taking specific long-term medications, cannot take part in the trial. Participants will provide stool samples, which will be analyzed to uncover important information about their intestinal bacteria and metabolites. This research could lead to better understanding and treatment options for appendicitis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 1-14 years who were initially diagnosed with appendicitis and underwent laparoscopic appendectomy
- • Children aged 1-14 years with non-digestive tract disease and no history of digestive tract disease
- Exclusion Criteria:
- • A family history of intestinal disease
- • Allergic to antibiotic therapy drugs
- • Patients with long-term drug use causing microbial structure changes or intestinal flora disorders
- • Patients with other congenital diseases such as Meckel's diverticulum, intestinal rotation and other malrotation
- • With other systemic diseases, such as obvious upper respiratory tract infection or myocarditis
- • Children with other digestive system diseases after auxiliary examination or surgical diagnosis
About Hongyiqu
Hongyiqu is a leading clinical trial sponsor dedicated to advancing medical research and innovation through robust clinical studies. With a focus on enhancing patient outcomes, Hongyiqu specializes in the design and execution of Phase I-IV trials across various therapeutic areas. The organization is committed to adhering to the highest ethical standards and regulatory requirements, ensuring the safety and efficacy of investigational products. Leveraging a team of experienced professionals and cutting-edge technology, Hongyiqu fosters collaboration with healthcare providers and stakeholders to expedite the development of groundbreaking therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Patients applied
Trial Officials
Qu
Study Chair
Shandong First Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported